{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:22Z","timestamp":1790668522098,"version":"4.1.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The article provides a commentary on a recently published study in which the veracity of global\/compendial Reference Standards for therapeutic recombinant human Erythropoietin (EPO) products is called into question. Here, we clarify the roles and intended uses of such standards, including the methods used in their value-assignment, and expand upon the potential causes of an apparent drift in unitage between EPO products from different geographical regions.<\/jats:p>","DOI":"10.1208\/s12248-026-01312-0","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:45:32Z","timestamp":1789152332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary on \u201cReference Standard Calibration Challenges in the Case of Erythropoietin: Impact on Potency and Biosimilarity Determination\u201d"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-592X","authenticated-orcid":false,"given":"Ben","family":"Cowper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rigsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116895","volume":"262","author":"B Cowper","year":"2025","unstructured":"Cowper B, Moore M, Burns C. Therapeutic glycoprotein hormones: considerations for the use of in vitro alternatives to in vivo potency assays. J Pharm Biomed Anal. 2025;262:116895. https:\/\/doi.org\/10.1016\/j.jpba.2025.116895.","journal-title":"J Pharm Biomed Anal"},{"key":"1312_CR2","unstructured":"Erythropoietin concentrated solution. Ph. Eur. 10, 1316 (07\/2021)."},{"key":"1312_CR3","doi-asserted-by":"publisher","DOI":"10.31003\/USPNF_M29702_02_01","volume-title":"USP-NF","author":"USP","year":"2024","unstructured":"USP. Epoetin. In: USP-NF. Rockville, MD: USP; 2024. https:\/\/doi.org\/10.31003\/USPNF_M29702_02_01."},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ani9100754","volume":"9","author":"R Hubrecht","year":"2019","unstructured":"Hubrecht R, Carter E. The 3Rs and Humane Experimental Technique: Implementating Change. Animals. 2019;9:754. https:\/\/doi.org\/10.3390\/ani9100754.","journal-title":"Animals"},{"key":"1312_CR5","doi-asserted-by":"publisher","DOI":"10.31003\/USPNF_M3548_01_01","volume-title":"USP-NF","author":"USP","year":"2024","unstructured":"USP. Xxaaa124> erythropoietin bioassays. In: USP-NF. Rockville, MD: USP; 2024. https:\/\/doi.org\/10.31003\/USPNF_M3548_01_01."},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1208\/s12248-025-01175-x","volume":"28","author":"J TerWee","year":"2025","unstructured":"TerWee J, Wilson-Landy K, Wany Y, Hellman N. Reference Standard calibration challenges in the case of Erythropoietin: impact on potency and biosimilarity determination. AAPS J. 2025;28:26. https:\/\/doi.org\/10.1208\/s12248-025-01175-x.","journal-title":"AAPS J"},{"key":"1312_CR7","unstructured":"Burns C, Tiplady R, Hockley J. WHO International Collaborative Study of the proposed 3rd International Standard for Erythropoietin, recombinant, for bioassay. WHO Expert Committee on Biological Standardization, Geneva, 15\u201319 October 2012. WHO\/BS\/2012.2195."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01312-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01312-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:20Z","timestamp":1790665400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01312-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":7,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01312-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employees of the UK Medicines and Healthcare products Regulatory Agency (MHRA), which encompasses NIBSC reference materials, including the WHO International Standard for EPO bioassays, 11\/170","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"148"}}